应用RT-PCR方法定量分析大肠癌患者多药耐药基因表达水平及其临床意义  

Quantitative Analysis of MDR 1 Gene Expression in Human Colorectal Carcinoma

作　　者：刘冀龙[1] 董新舒[1] 刘忠臣[1] 田野[1] 

机构地区：[1]哈尔滨医科大学第三临床医院腹外一科

出　　处：《中国肿瘤临床》1999年第1期39-41,共3页Chinese Journal of Clinical Oncology

基　　金：黑龙江省自然科学基金

摘　　要：目的：探讨大肠癌患者多药耐药与组织学分级和临床病理学Ｄｕｋｅｓ分期之间的关系。方法：采用逆转录－聚合酶链反应（ＲＴ－ＰＣＲ）的方法检测了６０例大肠癌患者肿瘤组织的ｍｄｒ－１表达水平，同时检测了其中２０例大肠癌患者的正常大肠组织作为对照。结果：高、中、低分化大肠癌组织之间ｍｄｒ－１表达水平具有极显著差异，大肠癌组织和正常大肠组织之间ｍｄｒ－１表达水平具有极显著差异，Ｄｕｋｅｓ分期的不同期之间ｍｄｒ－１表达水平无显著差异。结论：临床检测大肠癌患者ｍｄｒ－１基因的表达，可以预测患者对化疗的敏感性，从而进行有针对性的治疗，使化疗个体化。Objective: To evaluate the relationship between multidrug resistance of colorectal carcinoma and histological differentiation and Dukes clinicopathological staging. Methods: The expression of multidrug resistance (mdr 1 mRNA) was measured in 60 colorectal carcinoma samples and 20 normal colorectal tissues with RT PCR (reverse transcription polymerase chain reaction). Results: The level of mdr 1 gene expression in colorectal carcinoma appears correlating with the degree of histological differentiation,but not with the Dukes stage of the tumor. The difference of the level of mdr 1 gene expression between colorectal carcinoma and normal colorectal tissues is very remarkable. Conclusion: Measuring the expression of mdr 1 gene in colorectal carcinoma may predict the patients sensitivity to chemotherapy so that one can individualize the chemotherapy protocol for the patient.

关 键 词：大肠肿瘤 多药耐药基因 逆转录 聚合酶链反应 

分 类 号：R735.340.2[医药卫生—肿瘤]